Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates

Current Opinion in Pediatrics

Volumn 26, Issue 2, 2014, Pages 139-145

  Messier, Amber M ^a   Ohls, Robin K ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Erythropoiesis stimulating agents; Neurodevelopment; Neuroprotection; Oligodendrogenesis

Indexed keywords

ANTIANEMIC AGENT; CYTOKINE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NEUROPROTECTIVE AGENT;

APOPTOSIS; ASTROCYTE; BIRTH WEIGHT; BRAIN DEVELOPMENT; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WHITE MATTER; ANALOGS AND DERIVATIVES; ANIMAL; CHILD DEVELOPMENT; DRUG ADMINISTRATION; HYPOXIA-ISCHEMIA, BRAIN; NEWBORN; PATHOPHYSIOLOGY;

ANIMALS; CHILD DEVELOPMENT; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HEMATINICS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; INFANT, PREMATURE; NEUROPROTECTIVE AGENTS;

EID: 84897026329     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000077     Document Type: Review

References (52)

1. Stephens BE, Vohr B. Neurodevelopmental outcome of the premature infant. Pediatr Clin North Am 2009; 56:631-646.
2. Volpe JJ. The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Semin Pediatr Neurol 2009; 16:167-178.
3. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999; 2:148-158.
4. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43:40-49.
5. Chin K, Yu X, Beleslin-Cokic B, et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 2000; 81:29-42.
6. Mazur M, Miller RH, Robinson S. Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury. J Neurosurg Pediatr 2010; 6:206-221.
7. Masuda S, Chikuma M, Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res 1997; 746:63-70.
8. Blondeau N, Plamondon H, Richelme C, et al. K(ATP) channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal neuroprotection. Neuroscience 2000; 100:465-474.
9. Johns L, Sinclair AJ, Davies JA. Hypoxia/hypoglycemia-induced amino acid release is decreased in vitro by preconditioning. Biochem Biophys Res Commun 2000; 276:134-136.
10. Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60:386-392.
11. Byts N, Samoylenko A, Fasshauer T, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ 2008; 15:783-792.
12. Juul SE, Beyer RP, Bammler TK, et al. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009; 65:485-492.
13. McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010; 22:139-145.
14. Wei L, Han BH, Li Y, et al. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the Whisker-Barrel cortex of neonatal rats. J Pharmacol Exp Ther 2006; 317:109-116.
15. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98:4044-4049.
16. Bryl E, Myśliwska J, Dȩbska-Ś lizień A, et al. The influence of recombinant human erythropoietin on tumor necrosis factor a and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 1998; 22:177-181.
17. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, et al. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003; 18:2538-2544.
18. Kessaris N, Fogarty M, Iannarelli P, et al. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat Neurosci 2006; 9:173-179.
19. Back SA. Perinatal white matter injury: The changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev 2006; 12:129-140.
20. Buser JR, Maire J, Riddle A, et al. Arrested preoligodendrocyte maturation contributes to myelination failure in premature infants. Ann Neurol 2012; 71:93-109.
21. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and poststroke recovery. J Neurosci 2006; 26:1269-1274.
22. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002; 129:505-516.
23. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100:2279-2288.
24. Knabe W, Knerlich F, Washausen S, et al. Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat Embryol (Berl) 2004; 207:503-512.
25. Digicaylioglu M, Garden G, Timberlake S, et al. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA 2004; 101:9855-9860.
26. Jantzie LL, Miller RH, Robinson S. Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury. Pediatr Res 2013; 74:658-667.
27. Fan X, Heijnen CJ, van der KM, et al. Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res 2011; 69:56-61.
28. Kako E, Kaneko N, Aoyama M, et al. Subventricular zone-derived oligodendrogenesis in injured neonatal white matter in mice enhanced by a nonerythropoietic erythropoietin derivative. Stem Cells 2012; 30:2234-2247.
29. Liu W, Shen Y, Plane JM, et al. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol 2011; 230:227-239.
30. Yamada M, Burke C, Colditz P, et al. Erythropoietin protects against apoptosis and increases expression of nonneuronal cell markers in the hypoxia-injured developing brain. J Pathol 2011; 224:101-109.
31. Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 2010; 41:1032-1037.
32. Levison SW, Chuang C, Abramson BJ, Goldman JE. The migrational patterns and developmental fates of glial precursors in the rat subventricular zone are temporally regulated. Development 1993; 119:611-622.
33. Gonzalez FF, Larpthaveesarp A, McQuillen P, et al. Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke 2013; 44:753-758.
34. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22:503-514.
35. Vairano M, Dello Russo C, Pozzoli G, et al. Erythropoietin exerts antiapoptotic effects on rat microglial cells in vitro. Eur J Neurosci 2002; 16:584-592.
36. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54:375-429.
37. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297:259-263.
38. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, et al. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 2002; 44:391-403.
39. Neubauer AP, Voss W, Wachtendorf M, et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010; 67:657-666.
40. Juul SE, McPherson RJ, Bauer LA, et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety. Pediatrics 2008; 122:383-391.
41. McAdams RM, McPherson RJ, Mayock DE, Juul SE. Outcomes of extremely low birth weight infants given early high-dose erythropoietin. J Perinatol 2013; 33:226-230.
42. Ohls RK, Christensen RD, Kamath-Rayne BD, et al. A randomized, masked, placebo controlled study of darbepoetin administered to preterm infants. Pediatrics 2013; 132:119-127.
43. Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Neurocognitive outcomes in former preterm infants administered darbepoetin or erythropoietin. J Invest Med 2013; 61:166.
44. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; CD004863.
45. Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; CD004868.
46. Leuchter RH, Gui L, Hagmann C, et al. Neuroprotective effects of early Epo in preterm infants: An MRI study. ESPR 2011; 52:028.
47. Elmahdy H, El-Mahshad A-R, El-Bahrawy H, et al. Human recombinant erythropoietin in asphyxia neonatorum: Pilot trial. Pediatrics 2010; 125:e1135-e1142.
48. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: Safety and pharmacokinetics. Pediatrics 2012; 130:683-691.
49. Roberts J, Beachy J, Yoder B, et al. DANCE (Darbe administration in newborns undergoing cooling for encephalopathy): Safety and pharmacokinetic trial. J Invest Med (in press).
50. Messe SR, McGarvey ML, Bavaria JE, et al. A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery. Neurocrit Care 2013; 18:75-80.
51. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40:e647-e656.
52. Andropoulos DB, Brady K, Easley RB, et al. Erythropoietin neuroprotection in neonatal cardiac surgery: A phase I/II safety and efficacy trial. J Thorac Cardiovasc Surg 2013; 146:124-131.